Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
20%(2 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_4
2
18%
Ph phase_3
7
64%

Phase Distribution

0

Early Stage

0

Mid Stage

9

Late Stage

Phase Distribution9 total trials
Phase 3Large-scale testing
7(77.8%)
Phase 4Post-market surveillance
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(10)
Terminated(1)

Detailed Status

Completed10
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 37 (77.8%)
Phase 42 (22.2%)

Trials by Status

completed1091%
terminated19%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_3

A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).

NCT00383019
completedphase_3

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

NCT00159653
completedphase_4

Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.

NCT00143208
completedphase_4

A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

NCT00140049
completedphase_3

Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension

NCT00219596
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT00383019Phase 3

A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).

Completed
NCT00159653Phase 3

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

Completed
NCT00143208Phase 4

Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.

Completed
NCT00140049Phase 4

A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

Completed
NCT00219596Phase 3

Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension

Completed
NCT00801437

Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

Completed
NCT00277498Phase 3

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Completed
NCT01206361

Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

Completed
NCT02278614Phase 3

Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients

Completed
NCT00912054Phase 3

DuoTrav APS Versus XALACOM® in Ocular Surface Health

Terminated
NCT00150267Phase 3

A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11